Clinical Trials Directory

Trials / Completed

CompletedNCT04462094

Comparison of CRP Levels, Neutrophil Count, and Clinical Outcomes of Low Dose Ketamine Between at Anesthesia Induction and at the End of Surgery in Patients Undergo Elective Laparotomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
68 (actual)
Sponsor
Udayana University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The effects of anesthesia and surgery can lead to stress responses that result in hormonal and metabolic changes in the body. The immune system and the nervous system communicate both ways, and it was found that nociception and proinflammatory cytokines play a joint regulatory role, i.e., increased production of proinflammatory cytokines can worsen the pain. Major surgery can trigger the release of cytokines such as IL-1, IL-6, and TNF-α.

Detailed description

The effects of anesthesia and surgery can lead to stress responses that result in hormonal and metabolic changes in the body. The immune system and the nervous system communicate both ways, and it was found that nociception and proinflammatory cytokines play a joint regulatory role, i.e., increased production of proinflammatory cytokines can worsen the pain. Major surgery can trigger the release of cytokines such as IL-1, IL-6, and TNF-α. The acute analgesic effect of ketamine is generally believed to be mediated through the blockade of the phencyclidine binding site of the N-methyl-d-aspartate (NMDA) receptor of nociceptive neurons. Ketamine can reduce the inflammatory response marked by a decrease in CRP levels to surgical trauma and can prevent secondary damage to tissues/organs that were not initially affected by surgery by reducing inflammation. This also reduces postoperative pain and analgesics.

Conditions

Interventions

TypeNameDescription
DRUGKetamine 0.3 mg/kg at end-of-surgeryKetamine 0.3 mg/kg at end-of-surgery (intravenously)
DRUGKetamine 0.3 mg/kg at anesthesia inductionKetamine 0.3 mg/kg at anesthesia induction (intravenously)

Timeline

Start date
2020-07-27
Primary completion
2020-09-30
Completion
2020-11-10
First posted
2020-07-08
Last updated
2020-11-12

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT04462094. Inclusion in this directory is not an endorsement.